NexgenRx Inc.
NEGXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.70 | -0.48 | -0.01 | 1.56 |
| FCF Yield | -11.36% | 3.63% | 1.49% | 0.69% |
| EV / EBITDA | -13.37 | 26.52 | 22.46 | 25.86 |
| Quality | ||||
| ROIC | 2.33% | 4.23% | 6.66% | -0.35% |
| Gross Margin | 74.32% | 81.93% | 79.64% | 85.60% |
| Cash Conversion Ratio | -3.81 | 2.94 | 0.67 | -8.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.51% | 9.04% | 14.31% | 16.12% |
| Free Cash Flow Growth | -331.22% | 135.10% | 109.96% | 117.46% |
| Safety | ||||
| Net Debt / EBITDA | -34.84 | -2.57 | -1.68 | -1.58 |
| Interest Coverage | 4.63 | 10.64 | 68.93 | 38.13 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19.46 | -15.05 | 5.66 | -59.98 |